Loading...

Home
ETF
OCGN

OCGN

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

OCGN News

Ocugen Reports Q4 and Full-Year 2025 Financial Results

5d agoNASDAQ.COM

Ocugen Q4 2025 Earnings Call Insights Highlight Growth and Strategic Developments

6d agoseekingalpha

Ocugen Reports Q4 2025 Financial Results

6d agoseekingalpha

OCUGEN REPORTS Q4 NET LOSS OF USD 17.706 MILLION

OCUGEN REPORTS Q4 OPERATING EXPENSES OF $16.802 MILLION

Ocugen Set to Announce Q4 Earnings on March 4

Mar 03 2026seekingalpha

OCU400 Clinical Trial Enrollment Completed

Mar 02 2026Newsfilter

Ocugen Advances OCU400 for Retinitis Pigmentosa with FDA Submission Plans

Feb 25 2026stocktwits

Ocugen Appoints Rita Johnson-Greene as CFO

Feb 09 2026seekingalpha

Ocugen Inc Announces $22.5 Million Stock Offering, Shares Drop 10.48%

Jan 21 2026Benzinga

Ocugen (OCGN) Prices 15 Million Share Offering at $1.50, Raising $22.5 Million

Jan 21 2026seekingalpha

Ocugen Prices 15 Million Share Offering at $1.50, Raising $22.5 Million

Jan 21 2026Globenewswire

Ocugen Inc Reports 46% Lesion Growth Reduction in Phase 2 Trial, Stock Rallies

Jan 16 2026Benzinga

Ocugen Reports Phase 2 Data for OCU410, 46% Lesion Reduction Achieved

Jan 15 2026Benzinga

OS Therapies (OSTX) Reports Positive OST-HER2 Data but Shares Drop 4.52%

Jan 15 2026Benzinga

Ocugen (OCGN) Reports 46% Lesion Reduction in OCU410 Mid-Stage Trial

Jan 15 2026seekingalpha